β-肾上腺素能拮抗剂治疗慢性糖尿病足溃疡:前瞻性随机双盲对照平行组研究方案
本研究为二期随机双盲对照平行组临床试验,在VANCHCS招募糖尿病足溃疡患者,比较标准治疗联合局部噻吗洛尔凝胶(Timoptic-XE®)与标准治疗联合安慰剂凝胶的疗效与安全性。研究周期最长31周,主要观察伤口愈合情况。
要点
- 局部噻吗洛尔可能促进糖尿病足溃疡愈合。
- 研究设计为随机双盲对照平行组二期试验。
- 主要结局为伤口愈合,同时评估安全性。
核心结论
- 局部应用β-肾上腺素能拮抗剂噻吗洛尔可能改善糖尿病足溃疡的愈合,但需本试验验证其疗效与安全性。
研究设计与样本
- 二期随机双盲对照平行组临床试验,设两个治疗臂:标准治疗联合局部Timoptic-XE®凝胶与标准治疗联合无生物活性凝胶(水凝胶安慰剂)。
- 研究对象为VANCHCS的糖尿病足溃疡患者,研究周期最长31周,包括2周筛选期、最长12周积极治疗期(治疗2周后增加一次确认访视)及4个月每月随访期。
- 受试者每日局部涂抹研究药物或安慰剂,持续12周或直至愈合(以先发生者为准),基线与每周随访12周收集伤口大小等数据,之后每月随访。
关键数值与推荐
- 主要观察指标为伤口愈合情况,通过测量伤口大小等数据评估。
- 治疗持续12周或直至愈合,每日用药一次。
临床怎么用
- 若试验结果阳性,局部噻吗洛尔可能成为糖尿病足溃疡标准治疗的新辅助疗法。
- 临床应用中需关注局部用药的安全性和耐受性。
局限性
- 研究方案未报告样本量、效应量、P值等统计指标。
- 研究在单一医疗系统(VANCHCS)进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic foot ulcers (DFUs) are the most common cause of leg amputations and their management is extremely challenging. Despite many advances and expensive therapies, there has been little success in improving outcomes of DFUs. In prior work our laboratory has examined the effects of beta-adrenergic antagonists (βAAs) on skin and skin-derived cells. We have shown that βAAs enhance the rate of keratinocyte migration, promote angiogenesis, and hasten wound healing in scratch wounds in vitro, in animal wound models, and in anecdotally reported cases of chronic wounds that healed successfully after topical application of the βAA timolol. Thus, we propose to test timolol directly on DFUs to determine if it improves healing above the current standard of care (SOC). This study will examine the efficacy and safety of topically applied beta-antagonist Timoptic-XE® (timolol maleate ophthalmic gel forming solution) in subjects with DFUs. METHODS/DESIGN: This is a phase two, randomized, double-blinded, controlled, and parallel-group clinical trial with two treatment arms, SOC plus topical Timoptic-XE® and SOC plus a non-biologically active gel (hydrogel, as placebo drug). Study subjects with a DFU will be selected from the Veterans Affairs Northern California Health Care System (VANCHCS). Study duration is up to 31 weeks, with three phases (screening phase for two weeks, active phase for up to 12 weeks, with an additional second consecutive confirmatory visit after 2 weeks, and follow-up phase comprising monthly visits for 4 months). Subjects will apply daily either the topical study drug or the placebo on the foot ulcer for 12 weeks or until healed, whichever comes first. Measurements of wound size and other data will be collected at baseline, followed by weekly visits for 12 weeks, and then a monthly follow-up period. DISCUSSION: This is a clinical translation study, moving the investigators' pre-clinical laboratory research into a translational study in which we will analyze clinical outcomes to assess for safety and estimate the efficacy of a topical beta-antagonist in healing of DFUs. The results from this trial may establish new treatment paradigms and safety profile for DFU treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03282981. Registered on June 14th, 2018.
引用
- Kaur R, Tchanque-Fossuo C, West K, et al. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study. Trials. 2020. PMID: 32513257. doi:10.1186/s13063-020-04413-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。